About the Division

The Division of Neurogenetics focuses on the diagnosis and treatment of people who have or are at risk of developing neurogenetic diseases. Most of these diseases are chronic and progressive disorders that typically require management over the patient’s life. We take a multidisciplinary approach in creating individualized treatment plans for patients with a range of neurogenetic conditions, including:

  • Hereditary spastic paraplegia (HSP)
  • Cerebellar ataxia
  • Niemann-Pick disease
  • Leukoencephalopathies
  • Mitochondrial diseases
  • Neurofibromatoses

Physicians, genetic counselors, fellows, residents and medical students have opportunities to participate in research and clinical trials that often lead to breakthroughs. We offer a cooperative, supportive environment that values the contributions of all participants, including (and especially) patients.

Goals and highlights

The overarching goals for the Neurogenetic Division are to correctly diagnose each patient’s specific disorder and manage and mitigate their symptoms as we search for more effective treatments. Physicians and genetic counselors work with researchers to identify genetic risk factors and specific biomarkers to select the right medications and therapeutics for each patient, including (but not limited to) immunotherapy. Patients are often invited to participate in research and clinical trials that may help their condition and advance our work toward cures for all patients.

Centers and clinics

  • Neurogenetic Disorders Clinic/Ataxia Clinic at CarePoint Gahanna

Residency and Fellowship

The Department of Neurology at the Ohio State University has a long history of a dedicated commitment to education. We have world-class faculty and staff, state-of-the-art amenities, and novel technologies, all of which enables trainees to gain experience in the management of complex pathologies and apply innovative and high-quality medical care for a diverse patient population. Learn more about our residency and fellowship programs.

Fellowship opportunity

Advancement, opportunity, and collaboration describe the research and scholarship efforts in The Department of Neurology and the Health Services Research Division. Our faculty members are engaged in a broad range of multidisciplinary efforts to bolster advances in the practice, teaching, and research of family medicine. Our successes are demonstrated by professional presentations, publications, and grant support. Investigator-initiated research drives the department toward its goal of being a nationally and internationally recognized leader in research and scholarship. Educational initiatives and research continue to produce state-of-the-art curricula, teaching strategies, and learning techniques that advance medical education at many levels, including medical student education, residency training, and continuing medical education. The Ohio State University College of Medicine has as its goal to expand research in health equity, social determinants of health, population health, and health services and implementation science as well as the reduction of health inequities among our patients and communities through care delivery and education. The new faculty member will have an important role in helping the college achieve its goals. For more information and to apply, visit the Health Services Research Fellow posting.

Our Team

Oscar Harari

Oscar Harari, PhD

  • Associate Professor of Neurology
KisanukiYasushi

Yasushi Kisanuki, MD

  • Associate Professor – Clinical
Victoria Klee, MS, LCGC

Victoria Klee, MS, LCGC

  • Assistant Professor
Roggenbuck_Jennifer_460x460

Jennifer Roggenbuck, MS, LGC

  • Assistant Professor

Research and clinical trials

  • Research at Ohio State includes the participation in the REDISCA study of spinocerebellar ataxia, which looks at natural history factors of patients.
  • Other ongoing clinical research includes studying the natural history and progression of primary lateral sclerosis in patients.
  • Additionally, Ohio State has participated in clinical trials of a new drug to treat cerebrotendinous xanthomatosis (CTX), a very rare disorder. Approval of the drug is expected in the next few weeks.

Subscribe. Get just the right amount of health and wellness in your inbox.